von Hippel-Lindau tumor suppressor: not only HIF's executioner
- PMID: 15162797
- DOI: 10.1016/j.molmed.2004.02.004
von Hippel-Lindau tumor suppressor: not only HIF's executioner
Abstract
Loss of von Hippel-Lindau (VHL) protein function results in an autosomal-dominant cancer syndrome known as VHL disease, which manifests as angiomas of the retina, hemangioblastomas of the central nervous system, renal clear-cell carcinomas and pheochromocytomas. VHL tumor suppressor is a specific substrate-recognition component of the E3 ubiquitin complex, which regulates proteasomal degradation of the subunit of the hypoxia inducible transcription factor (HIF). Impaired VHL complex function leads to accumulation of HIF, overexpression of various HIF-induced gene products and formation of highly vascular neoplasia. However, the ubiquitylating role of the VHL complex extends beyond its function in regulating HIF, as it appears to regulate the stability of other proteins that might be involved in various steps of oncogenic processes.
Similar articles
-
Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.Trans Am Ophthalmol Soc. 2004;102:75-9; discussion 79-81. Trans Am Ophthalmol Soc. 2004. PMID: 15747747 Free PMC article.
-
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.Am J Nephrol. 2004 Jan-Feb;24(1):1-13. doi: 10.1159/000075346. Epub 2003 Dec 3. Am J Nephrol. 2004. PMID: 14654728 Review.
-
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.Hum Mol Genet. 2001 May 1;10(10):1019-27. doi: 10.1093/hmg/10.10.1019. Hum Mol Genet. 2001. PMID: 11331612
-
The von Hippel-Lindau tumor suppressor gene.Exp Cell Res. 2001 Mar 10;264(1):117-25. doi: 10.1006/excr.2000.5139. Exp Cell Res. 2001. PMID: 11237528 Review.
-
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938. Oncogene. 2000. PMID: 11114720
Cited by
-
FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation.Cell Death Discov. 2024 Mar 23;10(1):151. doi: 10.1038/s41420-024-01919-2. Cell Death Discov. 2024. PMID: 38519492 Free PMC article.
-
PROTACs: Walking through hematological malignancies.Front Pharmacol. 2023 Feb 20;14:1086946. doi: 10.3389/fphar.2023.1086946. eCollection 2023. Front Pharmacol. 2023. PMID: 36909156 Free PMC article. Review.
-
VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.Biomol Biomed. 2023 Feb 1;23(1):26-36. doi: 10.17305/bjbms.2022.7850. Biomol Biomed. 2023. PMID: 36036061 Free PMC article. Review.
-
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.Front Chem. 2021 Jul 5;9:707317. doi: 10.3389/fchem.2021.707317. eCollection 2021. Front Chem. 2021. PMID: 34291038 Free PMC article. Review.
-
The Heterogeneity Metabolism of Renal Cell Carcinomas.Adv Exp Med Biol. 2021;1311:117-126. doi: 10.1007/978-3-030-65768-0_8. Adv Exp Med Biol. 2021. PMID: 34014538 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
